论文部分内容阅读
目的:探讨先期化疗对晚期卵巢癌患者癌组织、外周血及腹水中多药耐药基因MDR1表达的影响,进一步探讨癌组织、外周血及腹水三者中耐药基因表达是否具有一致性,同时评价先期化疗的临床疗效。方法:采用RT-PCR技术检测25例晚期卵巢癌患者先期化疗后癌组织、外周血及腹水中的MDR1表达情况,取同期手术的晚期卵巢癌患者31例作为对照;观察肿瘤细胞减灭术满意率及手术后CA125的下降情况。结果:先期化疗组MDR1在癌组织、外周血及腹水中表达率分别为40.0%、28.0%和32.0%;术前未化疗组MDR1表达率分别为35.5%、25.8%及29.0%,两组MDR1表达比较差异无统计学意义(P>0.05),两组组内比较差异亦无统计学意义(P>0.05);同时得出癌组织、外周血及腹水三者中耐药基因表达的一致性;先期化疗组肿瘤细胞减灭术满意率高于未化疗组,差异有统计学意义(P<0.05),先期化疗组手术后CA125水平下降明显,与未化疗组比较差异有统计学意义(P<0.05)。结论:晚期卵巢癌先期化疗后MDR1表达未见明显增高;癌组织、外周血白细胞及腹水癌细胞中MDR1表达具有一致性。先期化疗提高了晚期卵巢癌患者的肿瘤细胞减灭术满意率,加快了CA125水平的下降。
Objective: To investigate the effect of advanced chemotherapy on the expression of multidrug resistance gene MDR1 in cancer tissue, peripheral blood and ascites in patients with advanced ovarian cancer and to further explore whether the expression of multidrug resistance gene in cancer tissue, peripheral blood and ascites is consistent, meanwhile, Evaluation of the clinical efficacy of advanced chemotherapy. Methods: RT-PCR was used to detect the expression of MDR1 in 25 cases of advanced ovarian cancer patients with advanced ovarian cancer after chemotherapy, 31 cases of advanced ovarian cancer patients undergoing synchronous operation as control; Rate and decline of CA125 after surgery. Results: The expression rates of MDR1 in pre-chemotherapy group were 40.0%, 28.0% and 32.0% respectively in pre-chemotherapy group, 35.5%, 25.8% and 29.0% in non-chemotherapy group, respectively. The MDR1 (P> 0.05). There was no significant difference between the two groups (P> 0.05). At the same time, it was found that the expression of drug resistance genes in cancer tissues, peripheral blood and ascites were consistent . The satisfaction rate of tumor cytoreductive surgery in advanced chemotherapy group was significantly higher than that of non-chemotherapy group (P <0.05), and the level of CA125 decreased significantly in advanced chemotherapy group compared with non-chemotherapy group (P <0.05). Conclusion: The expression of MDR1 in advanced ovarian cancer was not significantly increased after advanced chemotherapy. The expression of MDR1 in cancer tissues, peripheral blood leucocytes and ascites carcinoma cells was consistent. Advanced chemotherapy increased the rate of tumor cytoreductive surgery in patients with advanced ovarian cancer satisfaction rate, speed up the decline of CA125 levels.